[CRIS] Curis, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.37 Change: 0.15 (4.66%)
Ext. hours: Change: 0 (0%)

chart CRIS

Refresh chart

Strongest Trends Summary For CRIS

CRIS is in the medium-term down -37% below S&P in 7 months. In the long-term down -97% below S&P in 12 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Curis, Inc. is engaged in the research, development, and commercialization of cancer therapeutics. It focuses on developing cancer drug candidates, including CUDC-907, an oral, small molecule drug candidate that is designed to inhibit histone deacetylase and phosphatidylinositol-3-kinase, or PI3K enzymes; CUDC-427, an oral, small molecule drug candidate, which is designed to promote cancer cell death by antagonizing inhibitor of apoptosis proteins; Erivedge, an orally-administered small molecule Hedgehog pathway inhibitor; and Debio 0932, a small molecule inhibitor of heat shock protein 90. It has collaborations with Genentech, Inc. and F. Hoffmann-La Roche Ltd. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -65.47% Sales Growth - Q/Q-16.81% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-37.73% ROE-51.38% ROI-41.08%
Current Ratio10.54 Quick Ratio Long Term Debt/Equity0.23 Debt Ratio0.11
Gross Margin96.5% Operating Margin-412.36% Net Profit Margin-440.57% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities64.06 M Cash From Investing Activities-40.58 M Cash From Operating Activities-7.76 M Gross Profit1.57 M
Net Profit-31.85 M Operating Profit-31.02 M Total Assets119.31 M Total Current Assets102.55 M
Total Current Liabilities9.73 M Total Debt27.38 M Total Liabilities31.69 M Total Revenue1.66 M
Technical Data
High 52 week2.83 Low 52 week0.62 Last close2.09 Last change0%
RSI23.68 Average true range0.18 Beta1.07 Volume507.06 K
Simple moving average 20 days-7.52% Simple moving average 50 days0.36% Simple moving average 200 days21.73%
Performance Data
Performance Week-9.13% Performance Month-1.42% Performance Quart-11.44% Performance Half7.73%
Performance Year10.58% Performance Year-to-date202.99% Volatility daily3.75% Volatility weekly8.39%
Volatility monthly17.2% Volatility yearly59.59% Relative Volume533.41% Average Volume155.61 K
New High New Low

News

2020-05-12 16:01:00 | Curis Reports First Quarter 2020 Financial Results

2020-05-05 08:00:00 | Curis to Release First Quarter 2020 Financial Results and Hold Conference Call on May 12, 2020

2020-04-07 08:00:00 | Curis to Present at 19th Annual Needham Virtual Healthcare Conference

2020-04-03 16:01:00 | Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2020-03-26 21:38:49 | Edited Transcript of CRIS earnings conference call or presentation 19-Mar-20 8:30pm GMT

2020-03-19 16:01:00 | Curis Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update

2020-03-19 14:30:00 | Curis, Inc. to Host Earnings Call

2020-03-12 08:00:00 | Curis to Release Fourth Quarter and Year-End 2019 Financial Results and Hold Conference Call on March 19, 2020

2020-02-27 08:00:00 | Curis Announces $30 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

2020-02-06 08:30:00 | Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170

2020-01-13 08:00:00 | CurisĀ® and DarwinHealth Announce Scientific Collaboration to Characterize Biomarkers and Tumor Subtype Alignments for Fimepinostat in DLBCL and Solid Malignancies

2020-01-08 16:31:00 | Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2020-01-07 08:05:00 | Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies

2019-12-23 18:24:45 | Should You Buy Curis, Inc. CRIS?

2019-12-22 08:33:42 | The Curis NASDAQ:CRIS Share Price Is Up 103% And Shareholders Are Boasting About It

2019-12-06 07:26:00 | Curis Provides First-Ever Demonstration that Targeting IRAK4 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study

2019-11-20 22:07:04 | Edited Transcript of CRIS earnings conference call or presentation 5-Nov-19 1:30pm GMT

2019-11-06 09:05:00 | Curis Abstracts for Fimepinostat and CA-4948 Accepted for Presentation at the 61st Annual Meeting of the American Society of Hematology

2019-11-05 07:00:00 | Curis Reports Third Quarter 2019 Financial Results

2019-10-31 16:16:00 | /U P D A T E D -- Curis, Inc./

2019-10-29 08:00:00 | Curis to Release Third Quarter Financial Results and Hold Conference Call on November 5, 2019

2019-10-04 16:05:00 | Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-09-26 08:00:00 | Curis to Present at Cantor Fitzgerald Global Healthcare Conference

2019-09-23 12:07:58 | We Think Curis NASDAQ:CRIS Needs To Drive Business Growth Carefully

2019-09-12 08:00:00 | Curis Announces Promotion of Bill Steinkrauss to Chief Financial Officer

2019-08-06 16:01:00 | Curis Reports Second Quarter 2019 Financial Results

2019-07-30 08:00:00 | Curis to Release Second Quarter Financial Results and Hold Conference Call on August 6, 2019

2019-07-25 15:49:56 | Could Curis, Inc.'s NASDAQ:CRIS Investor Composition Influence The Stock Price?

2019-07-05 16:01:00 | Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-06-12 07:00:00 | Curis Highlights Publication in Nature Cell Biology Identifying Cancer-Causing Form of IRAK4 in Patients with AML and MDS

2019-05-14 21:03:39 | Edited Transcript of CRIS earnings conference call or presentation 14-May-19 8:30pm GMT

2019-05-14 16:29:33 | Curis: 1Q Earnings Snapshot

2019-05-14 16:05:00 | Curis Reports First Quarter 2019 Financial Results

2019-05-07 08:00:00 | Curis to Release First Quarter Financial Results and Hold Conference Call on May 14, 2019

2019-05-06 08:00:00 | Curis Completes Mesothelioma Enrollment in CA-170 Study

2019-04-26 15:13:48 | Some Curis NASDAQ:CRIS Shareholders Have Taken A Painful 83% Share Price Drop

2019-04-10 08:00:00 | Curis Regains Compliance with Nasdaq Continued Listing Requirements

2019-04-05 16:30:00 | Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-03-27 22:16:54 | Edited Transcript of CRIS earnings conference call or presentation 26-Mar-19 8:30pm GMT

2019-03-26 16:17:25 | Curis: 4Q Earnings Snapshot

2019-03-26 16:00:00 | Curis Reports Fourth Quarter and Year-End 2018 Financial Results

2019-03-26 07:36:32 | The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

2019-03-25 12:05:51 | What's Driving The Rally In Microcap Biotech Curis?

2019-03-25 11:46:02 | Biotech News: Why Curis Stock Is Soaring Today

2019-03-25 09:26:00 | Curis' stock rockets on heavy volume after $135.7 million deal to sell portion of Erivedge royalties

2019-03-25 08:30:00 | Curis Sells Portion of Erivedge Royalties to Oberland Capital for up to $135.7 million

2019-03-25 07:30:00 | Curis to Release Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 26, 2019

2019-03-04 08:00:00 | Curis Announces Presentation at Cowen & Company 39th Annual Healthcare Conference

2019-02-04 07:00:00 | Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference

2019-01-29 09:30:02 | Has Curis CRIS Outpaced Other Medical Stocks This Year?